Search hospitals

>

Missouri

>

Kansas City

Saint Luke's Hospital of Kansas City

Claim this profile

Kansas City, Missouri 64111

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Heart Failure

Conducts research for Stroke

Conducts research for Coronary Artery Disease

437 reported clinical trials

44 medical researchers

Photo of Saint Luke's Hospital of Kansas City in Kansas CityPhoto of Saint Luke's Hospital of Kansas City in Kansas CityPhoto of Saint Luke's Hospital of Kansas City in Kansas City

Summary

Saint Luke's Hospital of Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Heart Failure, Stroke, Coronary Artery Disease and other specialties. Saint Luke's Hospital of Kansas City is involved with conducting 437 clinical trials across 553 conditions. There are 44 research doctors associated with this hospital, such as Michael Gibson, Timothy Pluard, Janakiraman Subramanian, and Keith Allen, MD.

Area of expertise

1

Breast Cancer

Global Leader

Saint Luke's Hospital of Kansas City has run 40 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
HER2 positive
2

Lung Cancer

Global Leader

Saint Luke's Hospital of Kansas City has run 37 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Saint Luke's Hospital of Kansas City

Breast Cancer

Lung Cancer

Heart Failure

Breast cancer

Amyloidosis

Pancreatic Cancer

Pancreatic Carcinoma

Non-Small Cell Lung Cancer

Colorectal Cancer

Heart Disease

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Luke's Hospital of Kansas City?

Where is Saint Luke's Hospital of Kansas City located?

Who should I call to ask about financial aid or insurance network?

What insurance does Saint Luke's Hospital of Kansas City accept?

What awards or recognition has Saint Luke's Hospital of Kansas City received?